Unum Therapeutics Announces New Appointments to its Board of Directors
July 29, 2019 07:05 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., July 29, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat...
Unum Therapeutics to Present at the Wedbush PacGrow Healthcare Conference
July 17, 2019 09:00 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., July 17, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat...
Unum Therapeutics Announces Regulatory Update from Phase 1 Trial with ACTR087
July 02, 2019 16:30 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., July 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat...
Unum Therapeutics Strengthens and Expands Leadership Team
June 13, 2019 18:06 ET
|
Unum Therapeutics Inc.
– Matthew Osborne Appointed as Chief Financial Officer –– Jessica Sachs Promoted to Chief Medical Officer –– Mert Aktar Appointed as Head of Business and Corporate Development – CAMBRIDGE, Mass.,...
Unum Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update
May 13, 2019 07:00 ET
|
Unum Therapeutics Inc.
- Advancing ACTR Clinical Programs in Non-Hodgkin Lymphoma, Multiple Myeloma, and HER2+ Advanced Cancers Through Dose Escalation Studies with Data Expected from All Four Ongoing Trials in Second Half...
Unum Therapeutics to Host First Quarter 2019 Financial Results Conference Call and Webcast on May 13, 2019 at 8:00 A.M. ET
May 06, 2019 07:00 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., May 06, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (Nasdaq: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat...
Unum Therapeutics to Present at Two Upcoming Investor Conferences
April 02, 2019 07:00 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat...
Unum Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
March 28, 2019 07:00 ET
|
Unum Therapeutics Inc.
- Advancing ATTCK-20-03 Phase 1 Trial in CD20+ Non-Hodgkin Lymphoma Toward Expansion Phase; Completing ATTCK-20-2 Study - - Continued Dose Escalation of ATTCK-17-01 Trial in Multiple Myeloma - -...
Unum Therapeutics to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast on March 28, 2019 at 8:00 A.M. ET
March 21, 2019 07:00 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (Nasdaq: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat...
Unum Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference 2019
March 05, 2019 07:00 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat...